Company financially hurting

[anonymous]

I believe the latter. I think decision is already made. Even if they hit 38 million, that still does not cover respiratory payroll..... let alone other sales and marketing expenses.

Who really honestly believes we’ll hit 38 million? We did 11 million last year we at 4 million the first Qtr. I seriously bet we don’t smell 38 million per year until 2022. There are PUD’s in my territory with 95% yupelri mkt shr. It’s easier to get and they feel it’s a better product. I’m starting to hear them going into the LTC channel now. So there goes that niche. No way we hit 38 million and I hope our jobs aren’t depending on that ridiculous number.

 

[anonymous]

A year and a half in and the financial’s don’t look so good.
The only place really making money is in LTC. Uhm, working on LTC modules for the “upcoming” meeting, while management is expanding a double secret sales force into LTC as we speak.

Wait a minute. Are we actually LTC reps or do we just like to pretend we are one?

 

[anonymous]

company now DOESN’T RETO PAY PAY RAISES.
Company charges Fee for documentation in your 401 annually
Pushes all quester out a week to push back bonus payment to earn extra money on bonus interest held
Not filling repository positions save money
Not filling executive positions. To save money


Think about it!

 

[anonymous]

A year and a half in and the financial’s don’t look so good.
The only place really making money is in LTC. Uhm, working on LTC modules for the “upcoming” meeting, while management is expanding a double secret sales force into LTC as we speak.

Ok....I’m listening. What else do you know?

 

[anonymous]

https://www.ds-pharma.com/ir/news/pdf/eir20191101.pdf

 

[anonymous]

So, SumitomoDainippon, whose pharmaceutical sales world wide equals about $4.2 Billion, pays $3 Billion for a company with cash on hand and bridge loans. All but one of the vants has less than 50 employees. I think the future of the company is made with this purchase---of there is a blockbuster in the house, everyone is a genius. If there is not, and many drugs in the pipeline are duds or another Lonhala, this company is going to fold like a deck of cards. Reminds me of going to Vegas and putting your life savings down on either red or black. Win big, or lose big.

 

[anonymous]

Yes...looks like Lonhola is having another “Lonhola like performance” year. I mean we are at 30% of forecast. $38 million good luck with that number. Going on 2yrs and I’m not sure if we’ve paid for launch regional dinners.

 

[anonymous]

If these Vants are so good, and their molecules are so promising, how come ROIVANT is letting them go to this shithole of a company?

PT Barnum was right!